Zenabis Global (TSX:ZENA) will use TruTrace Technologies’ (CSE:TTT; OTC:BKKSF) StrainSecure platform to collect, register, manage, track and publish verified testing data of its cannabis plant DNA and strains, and provide its customers with increased transparency about the authenticity, quality and origin of its products.
Under the program, TruTrace collects plant-testing data and performs genomic verification in plant batches, which are then registered in a block chain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical make up, can be tracked via the program.
In addition, Zenabis is joining the Shoppers Drug Mart and TruTrace medical cannabis verification pilot project announced last week at the World Cannabis Congress. Shoppers aims to improve industry accountability and patient outcomes through the pilot project.
In a statement, Zenabis chief revenue officer, David Lluncor, said the company is happy to be able to play a role in offering Canadian medical patients and adult-use consumers assurances that they are being supplied safe, high quality, cannabis and hemp CBD products.
TruTrace CEO, Robert Galarza, said the recent launch of the pilot project with Canada’s leading pharmacy brand demonstrates the importance of standardization and traceability in designing and evaluating treatment programs for patients.
Phase 1 of the pilot project is expected to be completed by July 31, with full production and implementation targeted for late November 2019.
